As al­lo­gene­ic cell ther­a­py ap­proach­es flour­ish, Cen­tu­ry loads up $160M to scale iP­SC plat­form for CAR-T, CAR-NK

La­lo Flo­res is con­fi­dent he’s found the way for­ward in cell ther­a­py.

The feel­ing, to be sure, is not ex­clu­sive. Thanks to splashy com­pa­nies like Al­lo­gene and Arti­va, bio­phar­ma is well aware of the promis­es of al­lo­gene­ic ther­a­pies as next-gen­er­a­tion al­ter­na­tives to the au­tol­o­gous CAR-Ts that have al­ready made it to the mar­ket. But few­er are talk­ing about a fin­er dis­tinc­tion with­in that al­lo­gene­ic group: Where do you find the cells to en­gi­neer and turn in­to a fi­nal off-the-shelf prod­uct?

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN